{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:19:03Z","timestamp":1784855943618,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018971","name":"Faculty of Pharmaceutical Sciences, Burapha University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006749","name":"Burapha University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006749","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.vhri.2025.101119","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T01:03:49Z","timestamp":1746147829000},"page":"101119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Utility and Budget Impact Analyses of Herpes Zoster Vaccines in Patients With Human Immunodeficiency Virus in Thailand"],"prefix":"10.1016","volume":"48","author":[{"given":"Nattanichcha","family":"Kulthanachairojana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatapat","family":"Hemapanpairoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanyanoot","family":"Santhaveesook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papassara","family":"Piboonsatsanasakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Fueymee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6 suppl","key":"10.1016\/j.vhri.2025.101119_bib1","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jaad.2007.08.046","article-title":"Herpes zoster: epidemiology, natural history, and common complications","volume":"57","author":"Weinberg","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.vhri.2025.101119_bib2","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s40121-024-01002-4","article-title":"The incidence of herpes zoster complications: a systematic literature review","volume":"13","author":"Giannelos","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"8","key":"10.1016\/j.vhri.2025.101119_bib3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/cid\/ciu1161","article-title":"Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort","volume":"60","author":"Grabar","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vhri.2025.101119_bib4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s40121-023-00822-0","article-title":"Systematic literature review of herpes zoster disease burden in Southeast Asia","volume":"12","author":"San Martin","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vhri.2025.101119_bib5","article-title":"Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"4","key":"10.1016\/j.vhri.2025.101119_bib6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-4632.2010.04715.x","article-title":"Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand","volume":"50","author":"Aunhachoke","year":"2011","journal-title":"Int J Dermatol"},{"issue":"22","key":"10.1016\/j.vhri.2025.101119_bib7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vhri.2025.101119_bib8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vhri.2025.101119_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/apc.2014.0121","article-title":"Vaccination in HIV-infected adults","volume":"28","author":"Crum-Cianflone","year":"2014","journal-title":"AIDS Patient Care STDs"},{"issue":"4","key":"10.1016\/j.vhri.2025.101119_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther Adv Vaccines"},{"issue":"12","key":"10.1016\/j.vhri.2025.101119_bib11","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.ophtha.2021.04.017","article-title":"Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the United States","volume":"128","author":"Lu","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.vhri.2025.101119_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40258-019-00491-6","article-title":"Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults","volume":"17","author":"McGirr","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"33","key":"10.1016\/j.vhri.2025.101119_bib13","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vhri.2025.101119_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/hiv.12311","article-title":"Live attenuated herpes zoster vaccine for HIV-infected adults","volume":"17","author":"Shafran","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.vhri.2025.101119_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-015-1753-y","article-title":"Herpes zoster-associated mortality in Europe: a systematic review","volume":"15","author":"Bricout","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vhri.2025.101119_bib16","article-title":"Trends in influenza and pneumococcal vaccine coverage in Thai patients with type 2 diabetes mellitus 2010-2018: experience from a tertiary diabetes center in Bangkok","volume":"20","author":"Thewjitcharoen","year":"2020","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"10.1016\/j.vhri.2025.101119_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05648-6","article-title":"Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014","volume":"20","author":"Mu\u00f1oz-Quiles","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101119_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-021-00397-1","article-title":"A retrospective study of survival and risk factors for mortality among people living with HIV who received antiretroviral treatment in a resource-limited setting","volume":"18","author":"Manosuthi","year":"2021","journal-title":"AIDS Res Ther"},{"issue":"4","key":"10.1016\/j.vhri.2025.101119_bib19","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","article-title":"Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis","volume":"3","author":"Mbinta","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"10","key":"10.1016\/j.vhri.2025.101119_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vhri.2025.101119_bib21","article-title":"Efficacy and safety of the recombinant zoster vaccine: a systematic review and meta-analysis","volume":"15","author":"Renate","year":"2023","journal-title":"Vaccin X"},{"issue":"7","key":"10.1016\/j.vhri.2025.101119_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2012.08.255","article-title":"PRM3 standard cost list for economic evaluation in Thailand","volume":"15","author":"Riewpaiboon","year":"2012","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2025.101119_bib25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1524-4733.2008.00440.x","article-title":"Health utilities in patients with HIV\/AIDS in Thailand","volume":"12","author":"Sakthong","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2025.101119_bib27","series-title":"Thai Diagnosis Related Group. TDRG Version 6.3","year":"2024"},{"issue":"6","key":"10.1016\/j.vhri.2025.101119_bib28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14737167.2020.1693267","article-title":"Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZVIN) trial","volume":"20","author":"Eriksson","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.vhri.2025.101119_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.vhri.2025.101119_bib30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s41669-023-00438-7","article-title":"Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States","volume":"7","author":"Salem","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.vhri.2025.101119_bib31","article-title":"Cost-effectiveness of the recombinant zoster vaccine among people living with HIV in Japan","volume":"44","author":"Sato","year":"2024","journal-title":"Value Health Reg Issues"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:28:34Z","timestamp":1752611314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"alternative-id":["S2212109925000445"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101119","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Utility and Budget Impact Analyses of Herpes Zoster Vaccines in Patients With Human Immunodeficiency Virus in Thailand","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101119"}}